Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Novartis International AG / Novartis announces secukinumab (AIN457) demonstrated superiority to Enbrel® in head-to-head Phase III psoriasis study. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
• FIXTURE trial of more than 1,300 moderate-to-severe plaque psoriasis patients showed superiority of secukinumab (AIN457) to Enbrel® (etanercept)
• All primary and secondary endpoints were met - FIXTURE is a pivotal trial for registration; Regulatory submissions for secukinumab (AIN457), a therapy targeting IL-17A, are on track for the second half of 2013
Help employers find you! Check out all the jobs and post your resume.
